U.S. Markets close in 2 hrs 18 mins

Axsome Therapeutics, Inc. (AXSM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
24.22-2.49 (-9.32%)
As of 01:40PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close26.71
Bid24.21 x 900
Ask24.24 x 1000
Day's Range24.02 - 25.98
52 Week Range19.38 - 78.00
Avg. Volume590,043
Market Cap912.893M
Beta (5Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)-3.35
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est86.00
  • Motley Fool

    Why Axsome Therapeutics Climbed Today While the Market Fell

    In a somewhat counterintuitive development, shares of Axsome Therapeutics (NASDAQ: AXSM) rose on Thursday even though the company pointed out several issues in the development of one of its drugs. Following the company's latest update on the affected program, one analyst reiterated his bullish outlook on the shares, and they rose by 5.5%. In a regulatory filing, Axsome said it provided an official response to the Food and Drug Administration (FDA) regarding the pending New Drug Application (NDA) its AXS-05 drug candidate.


    First Midwest Bank Trust Division Buys Axsome Therapeutics Inc, PROSHARES TRUST, iShares ...

    Joliet, IL, based Investment company First Midwest Bank Trust Division (Current Portfolio) buys Axsome Therapeutics Inc, PROSHARES TRUST, iShares Russell Mid-Cap ETF, ISHARES TRUST, Aurinia Pharmaceuticals Inc, sells Iovance Biotherapeutics Inc, Consumer Discretionary Select Sector SPDR, AT&T Inc, Avis Budget Group Inc, Cerus Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Midwest Bank Trust Division.

  • Motley Fool

    Buy These Stocks If You Want 126% to 206% Returns, Says Wall Street

    Shares of clinical-stage biotech companies can skyrocket in a short period based on positive clinical and regulatory news. With that said, let's look at two clinical-stage biotechs that currently boast significant upside potential if we go by average price targets assigned by Wall Street analysts: CRISPR Therapeutics (NASDAQ: CRSP) and Axsome Therapeutics (NASDAQ: AXSM).